GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Other Long Term Assets

Agenus (FRA:AJ8) Other Long Term Assets : €7.0 Mil (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Agenus Other Long Term Assets?

Agenus's other long-term assets for the quarter that ended in Mar. 2024 was €7.0 Mil.

Agenus's quarterly other long-term assets declined from Sep. 2023 (€10.4 Mil) to Dec. 2023 (€8.6 Mil) but then stayed the same from Dec. 2023 (€8.6 Mil) to Mar. 2024 (€7.0 Mil).

Agenus's annual other long-term assets declined from Dec. 2021 (€8.4 Mil) to Dec. 2022 (€4.2 Mil) but then increased from Dec. 2022 (€4.2 Mil) to Dec. 2023 (€8.6 Mil).


Agenus Other Long Term Assets Historical Data

The historical data trend for Agenus's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Other Long Term Assets Chart

Agenus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.28 3.39 8.44 4.20 8.56

Agenus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.13 8.54 10.37 8.56 7.00

Agenus Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.


Agenus (FRA:AJ8) Business Description

Traded in Other Exchanges
Address
3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus (FRA:AJ8) Headlines

No Headlines